Informations générales (source: ClinicalTrials.gov)
"ART REGISTRY : Rheumatoid Arthritis and Anti-TNF" (ART)
Observational [Patient Registry]
Assistance Publique - Hôpitaux de Paris (Voir sur ClinicalTrials)
novembre 2016
février 2025
08 février 2025
Rheumatoid arthritis (RA) is a complex and multifactorial autoimmune disease. The
biological treatments that are currently available for the treatment of RA are the
TNF-alpha inhibitors. Tumor necrosis factor (TNF) is a dominant cytokine in the
inflammatory process of rheumatoid arthritis. The anti-TNFs were the first to enter the
market, and they revolutionised the prognoses of patients with RA. They remain the most
common first-line biotherapy and are the most used at this time.
The French Society of Rheumatologists intends to coordinate a prospective national
registry study for this follow-up.
This registry will include 1500 RA patients from the start of treatment with anti-TNF-α
and then followed for 5 years, regardless of the therapeutic modifications occurring
thereafter.
This registry is an observational, multicentre, longitudinal, prospective registry study
The objectives of this registry is to contribute 1) to evaluate the therapeutic
management of patients; and 2) to improve this therapeutic management.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL SAINT CAMILLE | Raphaele SEROR | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Adult patients with RA,
- Patient in whom the specialist physician decides to start treatment with an anti-TNF
drug, regardless of the treatment line and regardless of the anti-TNF, including
infliximab, adalimumab, etanercept, certolizumab and golimumab, and their respective
biosimilar according to their arrival on the market
- Clinicians (hospital-based and private practice) who agree to adhere to the yearly
renewal of the hospital prescription
- Adult patients with RA,
- Patient in whom the specialist physician decides to start treatment with an anti-TNF
drug, regardless of the treatment line and regardless of the anti-TNF, including
infliximab, adalimumab, etanercept, certolizumab and golimumab, and their respective
biosimilar according to their arrival on the market
- Clinicians (hospital-based and private practice) who agree to adhere to the yearly
renewal of the hospital prescription
- Patient already treated by the same anti-TNF in the past (same drug).